NCT01290692View on ClinicalTrials.gov

Study To Test the Safety and Efficacy of TVI-Brain-1 As A Treatment for Recurrent Grade IV Glioma

PHASE2CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

December 31, 2013

Study Completion Date

February 28, 2014

Conditions
Grade IV GliomaGrade IV AstrocytomaGlioblastoma Multiforme
Interventions
BIOLOGICAL

TVI-Brain-1

Following surgery, tumor tissue is used to generate a cancer vaccine. Patients are vaccinated with neutralized cells to initiate an immune response. Following vaccinations, the patient's white blood cells are collected, the white blood cells are stimulated and expanded, and are then reinfused into the patient's blood.

Trial Locations (4)

54311

Aurora BayCare Medical Center, Green Bay

63110

Washington University, St Louis

64111

Saint Luke's Hospital, Kansas City

75246

Baylor University Medical Center, Dallas

Sponsors

Lead Sponsor

TVAX Biomedical
All Listed Sponsors
lead

TVAX Biomedical

INDUSTRY

NCT01290692 - Study To Test the Safety and Efficacy of TVI-Brain-1 As A Treatment for Recurrent Grade IV Glioma | Biotech Hunter | Biotech Hunter